{'fraction_non_alphanumeric': 0.027491408934707903, 'fraction_numerical': 0.0, 'mean_word_length': 4.715686274509804, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Management of B-Cell Lymphoma: Where Are We Now and Where Are We Going?

The main objectives of the symposium were to explore the current developments in the diagnosis and treatment of non-Hodgkin lymphoma (NHL). An overview of the hurdles and unmet needs in the management of indolent NHL were discussed, followed by the current and future perspectives for the treatment of indolent NHL. The topic of frontline treatment outcomes in diffuse large B-cell lymphoma (DLBCL), the most common type of high-grade NHL, was also explored with an emphasis on how outcomes could be improved.